In addition, studies have illustrated that CD4+ T‐cell ICOS expression increases in peripheral blood and tumor tissues of patients treated with anti‐CTLA4 for bladder cancer,54 breast cancer,55 and non‐small cell lung cancer.56 Here, CTLA4 is linked to urinary bladder carcinoma.